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Abstract:
The development of immune-checkpoint-inhibitors (ICIs) has led to promising
advancements in the treatment of patients with cancers, leading with the use of cytotoxic T
10

lymphocyte-associated antigen 4 (CTLA-4) as a negative regulator of T cell activation in the
mid-1990s. With the discovery of two ligands for program cell death protein-1 (PD-1) and
promising checkpoint blockades in 2010, this sparked a cascade of hallmark immunotherapy
drug patents, focusing on the mechanism of anti PD-1 and anti PD-L1 antibody inhibitors. Since
then, chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have emerged into the
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immuno-oncologic scene for treatment of hematological malignancies. These genetically
modified T-cells focus on the destruction cancer cells without the need of chemotherapy.

One Sentence Summary: The history of the immune system, immunotherapy, then CAR-T cell
therapy is discussed as an efficient method of combatting hematological (blood) cancers and
20

25

supported by clinical case studies.

Abbreviations: APC=antigen presenting cell; CKI=checkpoint inhibition; FDA=Food and Drug
Administration; ICIs=immune-checkpoint-inhibitors; CTLA-4=cytotoxic T lymphocyteassociated antigen 4; PD-1=Programmed cell death protein-1; PD-L1=Programmed cell death
ligand-1; CAR=chimeric antigen receptor; PRRs=pattern recognition receptors; TLRs=Toll-like
receptors; MHC=Major histocompatibility complex; TAAs=Tumor-associated antigens;
Th=Helper T; Tc=Cytotoxic T; TCR=T cell receptor; ALL=acute lymphoblastic leukemia;
CRISPR=Cluster Regularly Interspaced Short Palindromic Repeats; IS=immunological synapse;
CTLs=cytotoxic T lymphocytes; scFvs=single-chain variable fragments
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Introduction
The Immune System
The immune system is a complex system made up of organs, tissues, cells, and molecules
that protects the human body from infection and diseases. Body responses are broken down into
5

two distinct categories: The innate immune response and the acquired immune response. The
innate immune system is composed of chemical and physical barriers such as acidic pH levels
within the stomach, the epithelial cells within the skin, and cilia lining the airways (1). If a
pathogen succeeds at breaching a chemical or physical barrier, macrophages will respond by
engulfing the unwanted substance. When pathogen concentration increases, pattern recognition
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receptors (PRRs) are activated, causing the release of cytokines, promoting inflammation and
recruiting other myeloid cells. Toll-like receptors (TLRs) activate transcription factor, NF-κB,
stimulating an inflammatory response and cytokine secretion, which causes vasodilation. Thus,
the acquired immune response is activated.
The immune system can identify a threat, mount an attack, eliminate a pathogen, and
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remember the offender if it were to be encountered again. The acquired immune response
consists of activated cells that differentiate between a diverse number of pathogens. Immune
cells, such as T cells and B cells, will undergo monoclonal expansion and later memorize
pathogenic substances to provoke a future, stronger response (1).
B cells express surface receptors that bind to specific antigens and can act as an antigen
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presenting cell (APC). Antigens are loaded onto the major histocompatibility complex (MHC) II
Complex which then displays the antigen to a T cell. When a T cell is activated by the B cell/T
cell conjugate, T cells will secrete cytokines that assist in B cell maturation into either a plasma
cell or memory B cells, which secrete antibodies into the serum to tag pathogens for destruction
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(Figure 1). T cells then mediate the destruction of the tagged pathogen via processes called
apoptosis and granule exocytosis (2).

Cancer and Immunotherapy
5

Cancer
Cancer is considered to be a genetic disease caused by the mutations of genes that control
the way cells grow and divide (3). This rapid duplication of cells may eventually lead to a tumor
through a process called carcinogenesis (1). While cancer cells are recognized as foreign
substances, the immune system fails to do so at times because some cancers may display similar

10

features as normal cell. This is due to inadequate eradication or due to the cancer cells displaying
similar features as normal cells. There are also some cases where the immune system may not
respond well enough to destroy a particular cancer, causing further metastasis.
Tumors can be classified into two categories. Benign tumors are a collection of abnormal
growing cells and are non-cancerous in nature. If these neoplastic cells were to break through the
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basement membrane of an epithelial cell and spread throughout the body, this would be defined
as metastatic disease, requiring immediate attention (3). Metastatic disease can lead to many
adverse effects depending on the location of the tumor and may necessitate treatments including
chemotherapy, radiotherapy, or immunotherapy.

20

Staging
Staging of one’s cancer is vital for clinicians to determine the location and severity of the
disease for proper management options. Although cancer is unpredictable, knowing the stage
may also help predict the course cancer will take based on the trend of previous data. Most
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importantly, staging of a tumor assists physicians help describe its characteristics to their patients
in order to make a decision that is right for them.
Although the TNM staging system is the most generally used cancer staging system,
leukemia staging is slightly different as leukemia derives from the bone marrow. Staging is
5

categorized based on one’s blood cell count and accretion of leukemia cells within the organs.
Not all leukemias are the same, as each subtype has its own individual differences in their
staging. For example, acute myeloid leukemia uses a cytologic (cellular) system which
characterizes the cancer based on the size and number of leukemia cells, change of appearance
within the chromosomes of leukemia cells, the number of healthy blood cells, and other genetic
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abnormalities that have occurred in the patient (Table 1) (5).

Immunotherapy
Radiation and chemotherapy were the standard of care treatment options for many who
were suffering from cancer. This changed in the early 2000s when a new approach to combatting
15

this deadly disease was discovered. Programmed cell death protein 1 (PD-1) is a protein found
on T cells that keep the body’s immune system in check (3). Programmed cell death ligand-1
(PD-L1) is a protein which acts as an inhibitor to the immune response and is found on normal
cells and in higher-than-normal amounts on certain cancer cells (3). When PD-L1 and PD-1 bind,
PD-L1 acts as an antagonist towards the T-cell programmed cell death mechanism allowing
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cancer to flourish and spread. The discovery of this mechanism led to the creation of many
anticancer drugs that inhibit the antagonist interactions between PD-1 and PD-L1 through a
process known as checkpoint inhibition (CKI) (Figure 2). Diseases expressing high
concentrations of PD-1 and PD-L1 receptors include colorectal, lung, gastric, bladder,
pancreatic, prostate, and diffuse large B-cell lymphoma (6).
4

By 2011, the first checkpoint inhibition drug, ipilimumab (Yervoy), was approved for
treatment for patients diagnosed with advanced melanoma (7). Within the next five years,
inhibitor drugs including nivolumab (PD-1 inhibitor), and atezolizumab (PD-L1 inhibitor) had
gained the approval by the Food and Drug Administration (FDA). CKI’s are currently being used
5

to treat various cancers such as non-small cell lung cancer, bladder carcinoma, melanoma, and
renal cell carcinoma with associated high response rates (7).
Immunotherapy has now changed the way physicians’ approach and treat numerous
cancers as some studies favor the use of immunotherapy over certain chemotherapy regimens
due to improved overall outcomes and significantly decreased adverse effects of cytotoxic
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therapies. The benefits over traditional treatments and rise in popularity have increased the
importance of continued research to new interactions between the immune system and its rival,
cancer cells.

Chimeric Antigen Receptor T Cells
15

Chimeric Antigen Receptors (CARs) are synthetic receptors that enable T cells to
recognize tumor-associated antigens (TAAs) (6). Normally, naïve T cells require costimulation
by an APC with an antigen loaded on its MHC class I or II molecules. In the case of a helper T
(Th) cell, its CD40L and CD28 ligands must interact with the APC’s CD40 and B7 respectively.
Cytotoxic T (Tc) cells also require costimulation for activation, however, only need the
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interaction of the CD40L and CD40. In the case of CAR T cells, these are synthesized to
recognize TAAs without the interaction of the T cell receptor (TCR)-MHC complex. Instead,
these CAR T cells will target the pan-B cell marker CD19 to activate its cell death mechanism
(Figure 3). CAR T cells have shown great response rates in treating refractory B cell
malignancies with drugs being implemented into clinical use (8).
5

CAR T cells emerged in 1993 by immunologist, Zelig Eshhar, when the first chimeric
molecule was fused to part of a TCR and tumor-specific cytotoxicity was observed. Later tests
proved these first-generation CAR T cells to be nonviable as they failed to elicit potent antitumor
effects. This process was almost forgotten until 2002 when the first effective second-generation
5

CAR T cell was created by the Memorial Sloan Kettering (MSK) Team (9). Second generation
CAR T cells containing a costimulatory domain, targeted prostate cancer antigens. Using second
generation cells were then modified to target the CD19 ligand which showed high efficacy in
destroying leukemia cells in mice (9). By the year 2013, the first human CAR T cell clinical trial
was published by the MSK group. Here, patients diagnosed with acute lymphoblastic leukemia
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(ALL) were treated with CD19 targeting CAR T cells showed significant response. This paved
the way for many new CAR T cell therapies. Scientists continued to develop this generation of
engineered cells and have since created “Armored CARs” that secrete active cytokines or
express ligands based on the specific tumor environment that further armor CAR T cells to
improve their efficacy and persistence. Cytokines included in the mechanism behind armored
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CAR T cells include IL-12, CD40L and 4-1BBL (10).
In recent years, the emergence of genome editing has played a vital role creating new
CAR T cell with improved recognition of cancer. Dr. Sadelain and colleagues have since been
able to use the genome-editing tool, Cluster Regularly Interspaced Short Palindromic Repeats
(CRISPR), to place a CAR at designated sites of T cells for boosted function (11). Sadelain was
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quoted saying the CAR T cells within the mice “retained their ability to kill tumor cells for much
longer than conventional CAR T cells, which burn out more quickly.” Essentially, this
mechanism involves the DNA slicing at a particular location with the insertion of a new gene
(11). The improved efficacy combined with an extended life-span of these CAR T cells results in
fewer cells required for therapy, the potential for decreased cytotoxicity, and improved tolerance
6

by the patient. The first CRISPR-CAR T cell clinical trial, “A Phase I Study of CTX130
Immunotherapy in People with Persistent or Recurrent T-Cell or B-cell Cancers,” is currently
underway in New York and is scheduled to be completed in 2027.

5

Mechanism
Classical cytotoxic T cell activation and function rely on the interaction with APCs and
the forces through the immunological synapse (IS). This includes the interactions of MHC I and
TCR as well as CD40 and CD40L. Disturbances of this synapse occur in the presence of various
cancers, decreasing the efficacy of CTLs. Engineered CAR T cells act independently of the IS
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and target tumor antigens independently of their presentations of antigens on MHC molecules
(12).
CAR T cells resemble both an antibody and TCR in the sense that they are recombinant
transmembrane receptors composed of an extracellular binding domain of a monoclonal antibody
single-chain variable fragments (scFvs) for the respective TAA, a hinge domain, and an
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intracellular signaling domain of a TCR molecule (CD3ζ). The next generation of CARs are
given a CD28 costimulatory domain proximal to the CD3ζ tail for supplementary signal strength
(13). These newer, engineered T cells are specifically designed to recognize specific tumor
antigens independent of an MHC expression complex.
In some cases, CKI drugs (anti PD-1, PD-L1, CTLA-4) may not work due to the cancer
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cells not properly expressing a sufficient amount of MHCs, causing T cells to remain inactive.
CAR T cells avoid this because they act independently of MHC. Once the CAR T cell comes in
contact with a cancer cell, signaling events induce and granule exocytosis, cytokine secretion,
and T cell proliferation is conducted.

7

Generations of CAR T-cells
The second generation of CAR T cell frequently imbues a CD28 costimulatory domain
nearing the CD3𝜁𝜁 tail to forte the activity of the CAR through phosphatidylinositol-3-kinase
(PI3K) signaling (Figure 4b).
5

The third generation of CAR T cells focus on the additional costimulatory ligand 4-1BB,
which joins CD28 at the intracellular domain. This connection prolongs the tenacity of the
cytotoxic effects of a CAR T-cell through the extracellular signal-regulated kinase (ERK) signal
(Figure 4b). The 4-1BB stimulus augments the CAR T-cell purpose and perseverance through
the NF-𝜅𝜅B signaling, encourages T-cell differentiation to central memory cells and protects
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against CAR T-cell exhaustion, allowing for a long-term purging of tumor cells (13).
Another third generation emphasizes the interaction between CD28-OX40. This
costimulatory signal induces a significant increase in the production of IL-2 and IL-10 cytokines
when compared with its older sibling of the second-generation CAR T-cell (14). The heightened
expression of IL-2 and IL-10 is beneficial for the effector functions and persistence of CAR T-
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cells in vivo.
The fourth generation of CAR T-cell uses single costimulatory domains that elevate the
expression of cytokines like IL-12, dispersing the intracellular signal from the costimulatory
molecules like PD-1 (14). This results in the improvement of the efficiency of the CAR T-cell
death mechanism (Figure 4b). A single activation of CAR instantaneously induces numerous

20

signaling events including the release of perforin granzymes, cytokine secretion, and T-cell
proliferation (14). Once the cancer cells are destroyed, some of the remaining T-cells become
memory lymphocytes for future recurrences.
The peripheral molecules of the immunological synapse play significant regulatory
functions on signaling the cytotoxic mechanism. This immunological synapse heavily relies on
8

adhesion molecules such as LFA-1 and talin. The engagements of these adhesion molecules play
important roles in antigen recognition. Once these adhesion molecules are engaged with the
antigen, this will result in a dampening of the TCR ligand density requirement for necessary
signaling, increase the affinity of LFA-1 to the intercellular adhesion molecule 1 (ICAM-1), and
5

LFA-1 ligation would boost actomyosin forces, further increasing the affinity of other
glycoproteins on T-cells (15, 16, 17). The overall improved T-cell adhesion results in
stabilization of the CAR TCR immunological synapse and extended signaling.

Synergies
10

There are additional factors that affect CAR T-cell signaling induction. The first is the
action of actomyosin. When the CAR TCR ligates with its respective antigen, actomyosin
synergistically polymerize retrograde flow in the immunological synapse. Retrograde flow
involves the actin filaments located in the leading edge of the migrating T-cell and flowing back
into the body of the cell, creating an efficient binding of the TCR–pMHC and CAR–antigen
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complex. T-cells will create F-actin-rich overhangs, organizing the secretion of perforins (18).
Actomyosin polymerization encourages the dispersion of T-cells across its cell surface for
optimal antigen–receptor binding.
Microtubules are also vital mechanisms of the CAR TCR immunological synapse (19).
The microtubules aid as the supporting framework to guide the reorientation of centrosome in the
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direction of the antigen-receptor complex (20). This transformation process is important for the
release of lytic granules in central immunological synapse. Microtubules also regulate the killing
efficiency of CAR T-cell. They act as anchors for the cytotoxic granules and transport the
granules toward the center of the immunological synapse, inducing the rapid secretion of lytic
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granules for the imminent cytolysis of cancer cells (21). The secretion of granules is much faster
in the CAR T-cell mechanism when compared to the typical CTL death process.

Metabolism
5

CAR T-cell activation initiates remodeling and influences numerous chromatins and
organelles, which are mirrored in the change of metabolic status of the T-cell. The metabolism of
T-cell governs the progression of the immune responses. A naïve T-cell typically has low-rate
fatty acid metabolism, which require remarkable upregulation upon activation (22). Given this,
naïve and memory T-cell development rely heavily on oxidative phosphorylation and
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mitochondrial metabolism. Phenotypic transformation is conducted with the activation of naïve
CD8+ T-cells. Glycolysis is enhanced to meet the energetic demands for the rapid proliferation,
force generation, signaling transduction, and production of cytolytic granules in the activated Tcell (22). CD28 costimulation has been reported to enhance the signaling by the CAR TCR
through the PI3K signaling and effectively elevates glycolysis and mitochondrial oxidative
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metabolism of the activated CTLs through the upregulated expression of glucose transporter 3
(GLUT3) to fulfill effector functions (23). Increased metabolism results in the synthesis of
metabolic enzymes including pyruvate kinase and oxidized nicotinamide adenine dinucleotide
(NAD+), both of which partake the histone acetylation and chromatin remodeling that regulate
the cytokine secretion of T lymphocytes (24).

20

Cytokine Release Syndrome
Cytokine Release Syndrome (CRS) is defined as a systemic inflammatory response that
can be activated by infection and therapeutic drugs (25). Given the growing success of CAR T
cell therapy, CRS has been at the forefront of debate regarding the genetically-engineered cell’s
10

safety when administered to patients. Research has shown CD19-targeted T cells revealed that
CRS is the most significant adverse event, with cytokine storms being reported upwards of 100%
of the patients within the clinical trials (Table 1) (26, 27).
CRS usually begins with flu-like symptoms including headache, fatigue, and arthralgia. If
5

untreated or monitored, symptoms can worsen over time and become life-threatening in severity.
If the CAR T cells are unable to stop signaling the inflammatory response of the immune system,
lab abnormalities will begin to arise, such as increased creatinine, liver enzymes, and cytopenias
(25). If treatment is not adjusted, this may result in intravascular coagulation and possible organ
failure.

10

Recent studies have shown progression in controlling CAR T cell induced CRS.
Currently, inhibiting IL-6R has been approved for treatment of CRS. Additionally, in 2019,
Sterner and colleagues investigated in targeting monocytes and macrophages by neutralizing
granulocyte macrophage colony-stimulating factor (GM-CSF) (28). This study involving GMCSF and CD19 targeted CAR T cells have since entered Phase II studies.

15

Clinical Trials
Many clinical trials have been published in support the use of CAR T-cell therapy. Wang
and colleagues published their findings in April 2020 with the use of their anti-CD19 drug, KTEX19 in relapsed or refractory mantle-cell lymphoma. In this phase-II clinical trial, 60 patients
20

who had up to five previous therapies, including the use of BTK inhibitor therapy underwent
leukapheresis, optional bridging therapy, followed by conditioning chemotherapy. Patients’ Tcells were genetically altered and given back in a single-infusion setting (29).
Results of the clinical trial were promising. Objective response expression was 93%, 67%
being a complete response (29). At the median follow-up of 12.3 months, 57% remained in
11

remission (29). One-year Progression-free survival and overall survival were noted to be 61%
and 83% respectively (29). Common adverse events of grade 3 or higher were cytopenias (in
94% of the patients) and infections (in 32%) (29). Grade 3 or higher cytokine release syndrome
and neurologic events occurred in 15% and 31% of patients, respectively; none were fatal (29).
5

Two grade 5 infectious adverse events occurred (Figure 5) (29).
A small phase I study was conducted in 2017 on patients diagnosed with refractory
diffuse large B cell lymphoma (DLBCL). Seven patients were treated with KTE-C19 CAR T
cells following three days’ worth of conditioning chemotherapy cyclophosphamide and
fludarabine. Five patients (71%) experienced an overall response with four (57%) experiencing a
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complete response (30). Three patients were noted to have ongoing complete responses at the 1year mark (30). Toxicities were noted within the study (one patient with grade 4 cytokine release
syndrome, one with grade 3 neurotoxicity), however, all resolved within one month (30). Given
the safety and effectiveness of the trial, phase II was strongly recommended for patients with
refractory DLBCL.

15

Finally, a study investigating the efficiency in relapsed or refractory multiple myeloma in
2019 also showed promising results where CAR T cells targeted B-cell maturation antigens
(BCMAs). In this phase I study, 33 patients diagnosed with relapsed/refractory multiple
myeloma were given bb2121 CAR T cell infusions following at least three lines of previous
therapy (31). The objective response rate 6 months following their last infusion was 85%

20

including fifteen patients (45%) visualizing complete responses (31). Unfortunately, six of the
fifteen patients experienced a relapse (31). Median progression-free survival was 11.8 months
with the CAR T cells persisting in the bodies of the patients up to 1 year after the first set of
infusions (31). Raje concluded antitumor activity was distinguished with BCMA-targeted CAR T
cell immunotherapy.
12

CAR T-cell combined with chemotherapy
Many clinical trials have shown that CAR T-cell monotherapy had insufficient efficacy to
treat solid tumors including trials with patients diagnosed with renal carcinoma and
5

neuroblastoma, though the mechanistic reasons for failure are unknown (32, 33, 34).
Combination of CAR T-cell therapy and chemotherapy have been suggested to show possible
synergetic capabilities in the future (35, 36). Chemotherapy agents such as cyclophosphamide,
fluorouracil, doxorubicin, oxaliplatin, and gemcitabine, are capable of reducing tumor burden
(37). Chemotherapy is able to sensitize tumor cells by upregulating mannose-6-phosphate
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receptors on tumor cell surfaces. This results in the release of granzymes by CTLs to pervade
tumor cells, sensitizing tumor cells to immunotherapy (38).
Mechanistically, some chemotherapy agents may induce autophagy resulting in the
release of ATP and increasing the recruitment of dendritic cells (DCs) and CTLs. Dying cancer
cells secrete damage-associated molecular patterns (DAMPs) which are recognized by TLR4. By
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promoting DC activation, T-cell response is also increased. Chemotherapy is noted to also create
type I interferons (interferon alpha and interferon-beta) which also promote DC activation in the
innate immune response system (39). This trickle-down effect leads to interferon-gamma
secretion by DCs and activation of the adaptive immune response.
Radiotherapy may also create synergetic effects as studies have shown sensitizing tumor
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cells have reportedly demonstrated improved MHC I molecules for CD8+ CTLs to bind to the
tumor-specific sites. Radiographic areas also promote the release of Interferon-gamma and
DAMPs, resulting in the activation of T lymphocytes. Given the excitation of DAMPs, it can be
assumed tumor antigen presentation is also improved due to canonical mechanism of DC
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maturation via type I interferon environment, serving as a connecting bridge of the innate to
adaptive immune system (40).

CAR T cells efficiency and battle against solid tumors
5

CAR T cells encounter a number of challenges to combat the complex state of a solid
tumor. For promising results, CAR T cells must meet a sequential order of tasks to be effective.
Currently, these cells lack the unique TAAs, are inefficient in targeting the specific tumor site,
and remain weak to the immunosuppressive environment of solid tumors. TAAs are diverse as
they contain novel peptide sequences, are expressed in a specific sequence, can be expressed
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during fetal development or at immunocompromised states, and expressed higher when tumor
cells are prevalent (41). If a TAA sequence, expression, and prevalence is compromised, CAR T
cell effectiveness diminishes. ‘On target/off tumor,’ or a direct attack on normal tissues that have
the shared expression of a target antigen, side effects may occur due to the overexpression of
those antigens (41).
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The interest in modifying CAR T cells to effectively neutralize a solid-state tumor
launched many continued trials. A study by Adachi and colleagues in 2018 confirmed CAR T
cell survival and infiltration into solid tumors relies heavily on IL-7 and CCL19 expression (42).
Chemokine ligand 19 (CCL19), a protein that is involved in immunoregulatory and
inflammatory processes. It is suggested that the cytokine encoded by this gene may play a role in
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normal lymphocyte recirculation, homing, and T cell trafficking. Knowing this, Adachi was able
to implement both IL-7 and CCL19 with results showing abrogated the migration of responder
cells, suggesting that the modified CAR T cells mediated their chemotactic activity. The
investigation was continued in vivo using mouse models and a specified tumor. The mice were
treated with conventional or IL-7/CCL19 modified CAR T cells.
14

Results favored the IL-7/CCL19 as this induced a complete regression of the tumor,
leading to long-term survival of the mice without tumor recurrence (42). It was also noted that
dosing of the IL-7/CCL19 was increased which correlated to increased mice survival, suggesting
conventional CAR T cells have tumor-lytic capabilities. Immune checkpoint molecules were also
5

investigated in vivo. It was found that PD-1, lymphocyte-activation gene 3 (LAG3), and T cell
immunoreceptor with immunoglobulin and ITIM domains (TIGIT) on the IL-7/CCL19 CAR T
cells were lower when compared to the conventional CAR T cells (42). This proposes and
confirms the idea of IL-7 signaling can prevent and/or restore T cell exhaustion.
Adachi noted the IL-7/CCL19 CAR T cells were considered to be a third-generation line
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as it consisted of the CD3ζ, CD28, and 4-1BB domains (42). Second-generation CAR T cells are
considered to exercise a more potent anti-cancer effect when compared to the third generation
(Zhong 2010 – CAR combining 4-1BB and CD28 signaling domains augment). Finally, the IL7/CCL19 cells were tested in mice expressing Lewis lung carcinoma showing prolonged
survival, although debated whether a new target should be selected (42).
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Alizadeh and colleagues also investigated the efficiency of a CAR T cell and concluded
cytokine IL-15 promotes T cell antiapoptotic factors and inhibits T cell exhaustion. It was also
determined that IL15 enhances the antioxidant capacity of T cells, resulting in amplified T cell
perseverance (43). Correlating with the inhibition of T cell exhaustion was the lowered
expression of PD-1, LAG3, and 2B4 checkpoint inhibitor molecules (43). Finally, IL-15 cultured
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CAR T cells exhibited less mammalian target of rapamycin (mTOR) activity and reduced
expression of glycolytic enzymes, suggesting the CAR T cells were in fact displaying antitumor
activity (43).

Conclusion
15

The use of CAR T cell therapy in patients expressing refractory B cell lymphomas have
presented positive outlooks on metastatic control and patient survival. These geneticallyengineered cells have been proven effective as patients receiving KTE-X19 concluded with
promising objective response, complete response, and progression-free survival rates. Although
5

cytopenia’s were experienced during the clinical case trial, “KTE-X19 CAR T-Cell Therapy in
Relapsed or Refractory Mantle-Cell Lymphoma,” Wang and collegues were able to implement a
safe, efficient approach to patients who previously exhausted first-line therapies including BTK
inhibitor treatment. Future studies on CAR T cell therapy may include combination therapeutics
alongside current chemotherapies and radiation for solid-state tumors.

10

The future of oncology and the administration of immunotherapy will continue to be a
challenge for practicing physicians and scientists worldwide. Understand how the human body
interacts with cancer cells is vital to the future of standard of care of patients diagnosed with
cancer. This will be accomplished by discovering new ligands and receptors on associated tcells, APC’s and cancer cells, providing new opportunities to combat this deadly disease.
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Fig. 1. Schematic Diagram of T cell activation. A dendritic cell (DC) carrying a peptide and
MHC molecule will come into contact with a T cell. The binding occurs through the MHC
complex. Co-stimulation will occur following CD86, CD80, OX40L and 4-1BBL binding. The
end result is full activation in the T cell (44).

Fig. 2. PD-1 (T cell) and PD-L1 (tumor cell) interaction. IFNγ will induce and maintain
expression of PD-L1. CKI’s will act as PD-1 and PD-L1 inhibitors to induce the cell death
mechanism of a T cell (45).
20

Fig. 3. Anatomy of a CAR T Cell highlighting major components (46).
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Fig. 4. Schematic Diagram of CAR T cells. A) Comparison of a classical TCR-MHC and
CAR-CD19. B) The generations of CAR T cell designs (13).
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5

Fig. 5. Objective Response, Duration of Response, Progression-free Survival, and Overall
Survival in XTE-X19 Phase 2 clinical trial (29). A) Number and percentages of patients with
an objective response (complete or partial). B) Duration of response. C and D) Progression free
survival and overall rates amongst the 60 patients, respectively.
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Table 1: CRS reported in clinical trials involving CD19-targeted CAR T cell therapeutic
agents.
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